Literature DB >> 32918523

Perspectives of Vietnamese, Sudanese and South Sudanese immigrants on targeting migrant communities for latent tuberculosis screening and treatment in low-incidence settings: A report on two Victorian community panels.

Chris Degeling1, Stacy M Carter1, Katie Dale2,3, Kasha Singh4, Krista Watts2, Julie Hall1, Justin Denholm2,3.   

Abstract

BACKGROUND: Tuberculosis (TB) elimination strategies in Australia require a focus on groups who are at highest risk of TB infection, such as immigrants from high-burden settings. Understanding attitudes to different strategies for latent TB infection (LTBI) screening and treatment is an important element of justifiable elimination strategies.
METHOD: Two community panels were conducted in Melbourne with members of the Vietnamese (n = 11), Sudanese and South Sudanese communities (n = 9). Panellists were provided with expert information about LTBI and different screening and health communication strategies, then deliberated on how best to pursue TB elimination in Australia.
FINDINGS: Both panels unanimously preferred LTBI screening to occur pre-migration rather than in Australia. Participants were concerned that post-migration screening would reach fewer migrants, noted that conducting LTBI screening in Australia could stigmatize participants and that poor awareness of LTBI would hamper participation. If targeted screening was to occur in Australia, the Vietnamese panel preferred 'place-based' communication strategies, whereas the Sudanese and South Sudanese panel emphasized that community leaders should lead communication strategies to minimize stigma. Both groups emphasized the importance of maintaining community trust in Australian health service providers, and the need to ensure targeting did not undermine this trust.
CONCLUSION: Pre-migration screening was preferred. If post-migration screening is necessary, the potential for stigma should be reduced, benefit and risk profile clearly explained and culturally appropriate communication strategies employed. Cultural attitudes to health providers, personal health management and broader social vulnerabilities of targeted groups need to be considered in the design of screening programs.
© 2020 The Authors. Health Expectations published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Australia; deliberative methodologies; latent tuberculosis; migrant health; population screening

Year:  2020        PMID: 32918523      PMCID: PMC7752196          DOI: 10.1111/hex.13121

Source DB:  PubMed          Journal:  Health Expect        ISSN: 1369-6513            Impact factor:   3.377


  45 in total

1.  "It is more than the issue of taking tablets": the interplay between migration policies and TB control in Sweden.

Authors:  Asli Kulane; Beth M Ahlberg; Ingela Berggren
Journal:  Health Policy       Date:  2010-03-29       Impact factor: 2.980

2.  Influencing health policy through public deliberation: Lessons learned from two decades of Citizens'/community juries.

Authors:  Chris Degeling; Lucie Rychetnik; Jackie Street; Rae Thomas; Stacy M Carter
Journal:  Soc Sci Med       Date:  2017-03-02       Impact factor: 4.634

Review 3.  Latent tuberculosis infection--Revisiting and revising concepts.

Authors:  Padmini Salgame; Carolina Geadas; Lauren Collins; Edward Jones-López; Jerrold J Ellner
Journal:  Tuberculosis (Edinb)       Date:  2015-05-15       Impact factor: 3.131

Review 4.  Reducing infectious disease inequities among migrants.

Authors:  Anita E Heywood; Rogelio López-Vélez
Journal:  J Travel Med       Date:  2019-02-01       Impact factor: 8.490

5.  Educational outreach to promote screening for tuberculosis in primary care: a cluster randomised controlled trial.

Authors:  Chris Griffiths; Pat Sturdy; Penny Brewin; Graham Bothamley; Sandra Eldridge; Adrian Martineau; Meg MacDonald; Jean Ramsay; Suresh Tibrewal; Sue Levi; Ali Zumla; Gene Feder
Journal:  Lancet       Date:  2007-05-05       Impact factor: 79.321

6.  Can Australia eliminate TB? Modelling immigration strategies for reaching MDG targets in a low-transmission setting.

Authors:  Justin T Denholm; Emma S McBryde
Journal:  Aust N Z J Public Health       Date:  2014-02       Impact factor: 2.939

7.  How effective are approaches to migrant screening for infectious diseases in Europe? A systematic review.

Authors:  Farah Seedat; Sally Hargreaves; Laura B Nellums; Jing Ouyang; Michael Brown; Jon S Friedland
Journal:  Lancet Infect Dis       Date:  2018-05-16       Impact factor: 25.071

Review 8.  An overview of tuberculosis and migration.

Authors:  P Dhavan; H M Dias; J Creswell; D Weil
Journal:  Int J Tuberc Lung Dis       Date:  2017-06-01       Impact factor: 2.373

9.  WHO's new end TB strategy.

Authors:  Mukund Uplekar; Diana Weil; Knut Lonnroth; Ernesto Jaramillo; Christian Lienhardt; Hannah Monica Dias; Dennis Falzon; Katherine Floyd; Giuliano Gargioni; Haileyesus Getahun; Christopher Gilpin; Philippe Glaziou; Malgorzata Grzemska; Fuad Mirzayev; Hiroki Nakatani; Mario Raviglione
Journal:  Lancet       Date:  2015-03-24       Impact factor: 79.321

10.  Poor uptake of primary healthcare registration among recent entrants to the UK: a retrospective cohort study.

Authors:  Helen R Stagg; Jane Jones; Graham Bickler; Ibrahim Abubakar
Journal:  BMJ Open       Date:  2012-08-06       Impact factor: 2.692

View more
  2 in total

1.  Detecting Mycobacterium tuberculosis Infection in Children Migrating to Australia.

Authors:  Ingrid Laemmle-Ruff; Stephen M Graham; Bridget Williams; Danielle Horyniak; Suman S Majumdar; Georgia A Paxton; Lila V Soares Caplice; Margaret E Hellard; James M Trauer
Journal:  Emerg Infect Dis       Date:  2022-09       Impact factor: 16.126

2.  Perspectives of Vietnamese, Sudanese and South Sudanese immigrants on targeting migrant communities for latent tuberculosis screening and treatment in low-incidence settings: A report on two Victorian community panels.

Authors:  Chris Degeling; Stacy M Carter; Katie Dale; Kasha Singh; Krista Watts; Julie Hall; Justin Denholm
Journal:  Health Expect       Date:  2020-09-12       Impact factor: 3.377

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.